• The FDA approves a new bulk toxin source for use in the manufacture of BoNT-A. The new product, currently called  Botox® (onabotulinumtoxinA), is comparable in clinical efficacy to the original Botox, but the higher specific potency reduces the amount of neurotoxin protein utilized, which in turn, leads to a reduction in the production of antibodies.